Skip to main content
. 2017 Apr 25;2(5):836–843. doi: 10.1016/j.ekir.2017.03.016

Table 4.

Most frequently reported adverse events for QPI-1002 versus placebo-treated patients Through day 30

Event QPI-1002, n (%) Placebo, n (%)
Hypotension 5 (41.7) 2 (50.0)
Pleural effusion 5 (41.7) 1 (25.0)
Anemia 3 (25.0) 2 (50.0)
Constipation 4 (33.3) 0 (0.0)
Nausea 3 (25.0) 0 (0.0)
Leukocytosis 3 (25.0) 2 (50.0)
Elevated AST 3 (25.0) 1 (25.0)
Pulmonary edema 3 (25.0) 0 (0.0)
Peripheral edema 3 (25.0) 0 (0.0)

AST, aspartate transaminase.